首页  /病理讲座


密  码:




  • 电话:+86 519 81889706
    传真:+86 519 81889706





【科研合作】喜讯!我公司与常州二院心胸外科合作课题成果发表于国际学术期刊PLoS One

更新日期:2015-08-20   返回上一页

 我公司与常州二院心胸外科合作课题发表于国际学术期刊PloS One(影响因子3.2)

 2015 Aug 3;10(8):e0134220. doi: 10.1371/journal.pone.0134220. eCollection 2015.

MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer.

Li W1Wang Y2Zhang Q1Tang L1Liu X1Dai Y1Xiao L1Huang S1Chen L1Guo Z3Lu J3Yuan K2.


  • Abstract


    Non-small cell lung cancer (NSCLC) is a leading cause of cancer death worldwide. Early diagnosis is essential for improvements of prognosis and survival of the patients. Currently, there is no effective biomarker available in clinical settings for early detection of lung cancer. Altered expressions in many cancer types including NSCLC and stable existence in plasma make microRNAs (miRNAs) a group of potentially useful biomarkers for clinical assessments of patients with NSCLC.


    To evaluate the potential values of miRNAs as blood-based biomarkers for early diagnosis and prognosis in NSCLC patients.


    Peripheral blood samples from healthy volunteers and early-staged NSCLC patients before and after surgery were collected, and plasma was separated. Expression of ten miRNAs in the plasma and tumor sections of the patients was detected by quantitative real-time polymerase chain reaction.


    MiRNA (miR)-486 and miR-150 were found to significantly distinguish lung cancer patients from healthy volunteers. Area under curve of miR-486 and miR-150 were 0.926 (sensitivity, 0.909; specificity, 0.818) and 0.752 (sensitivity, 0.818; specificity, 0.818), respectively. In response to therapy, patients with down-regulated miR-486 expression showed prolonged recurrence-free survival than those with un-reduced miR-486 expression (median, unreached vs. 19 months; hazard ratio, 0.1053; 95% confidence interval, 0.01045 to 1.060; P=0.056).


    The results suggest that miR-486 and miR-150 could be potential blood-based biomarkers for early diagnosis of NSCLC. Monitoring change of miR-486 expression in plasma might be an effective and non-invasive method for recurrence prediction of early-staged NSCLC patients.


本文第一作者为常州杰傲病理诊断技术有限公司李万帅(Li W)博士,通讯作者为常州二院心胸外科袁凯(Yuan K)博士和常州杰傲/美国杰傲卢正斌(Lu J)博士。本研究获得常州市科技支撑计划(社会发展)(项目编号CE20125002)支持。

我公司目前可提供细胞培养、蛋白电泳(Western Blot)、ELISA、实时荧光定量PCR、Sanger测序、芯片扫描、数字PCR等技术服务。热忱欢迎各院所、医院与我公司开展系统性科研合作,我们秉承优质、高效的原则,保证科研服务的质量。


关于杰傲 | 服务项目 | 杰傲新闻 | 联系我们 | 招贤纳士 | 网站管理 | 邮箱登陆
常州杰傲病理诊断技术有限公司 地址:江苏省常州市科教城常武中路801号天润科技大厦A座4楼(213164) 苏ICP备13021302号